Application of high throughput technologies to drug substance and drug product development

Computers and Chemical Engineering

Volumn 28, Issue 6-7, 2004, Pages 943-953

  Gardner, Colin R ^a   Almarsson, Orn ^a   Chen, Hongming ^a   Morissette, Sherry ^a   Peterson, Matt ^a   Zhang, Zhong ^a   Wang, Szu ^a   Lemmo, Anthony ^a   Gonzalez Zugasti, Javier ^a   Monagle, Julie ^a   Marchionna, Joseph ^a   Ellis, Steve ^a   McNulty, Chris ^a   Johnson, Alasdair ^a   Levinson, Doug ^a   Cima, Michael ^b  

^a TransForm Pharmaceuticals Inc   (United States)

^b USA   (United States)

Author keywords

Crystallization; Formulation; High throughput; Informatics; Pharmaceutical development; Polymorphs

Indexed keywords

CHEMICAL ANALYSIS; CHEMICAL ENGINEERING; HYDRATES; MEDICAL IMAGING; PERSONNEL; SALTS;

INFORMATICS; POLYMORPH;

DRUG PRODUCTS;

CYCLOSPORIN; PACLITAXEL; PROTEINASE INHIBITOR; RITONAVIR; SULFATHIAZOLE;

MEDICAL APPLICATION;

COMPUTER PROGRAM; COMPUTER SYSTEM; CONFERENCE PAPER; DATA ANALYSIS; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SCREENING; DRUG SOLUBILITY; EVALUATION; HIGH THROUGHPUT SCREENING; HUMAN; IMAGING; INFORMATION SCIENCE; SIDE EFFECT; TECHNIQUE; VALIDATION PROCESS;

EID: 11144357547     PISSN: 00981354     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.compchemeng.2003.09.028     Document Type: Conference Paper

References (11)

1. Almarsson, O., Hickey, M. B., Peterson, M. L., Morissette, S. L., Soukasene, S., McNulty, C., Tawa, M., MacPhee, J. M., & Remenar, J. F. (2003). High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds. Crystal Growth & Design (in press).
2. Bauer J., Spanton S., Henry R., Quick J., Dziki W., Porter W., Morris J. Ritonavir: an extraordinary example of conformational polymorphism. Pharmacological Research. 18:2001;859.
3. Beyer T., Day G.M., Price S.L. The prediction, morphology and mechanical properties of the polymorphs of paracetamol. Journal of the American Chemical Society. 123:2001;5086.
4. Burger A. Interpretation of polymorphism studies. Acta Pharmaceutica Technologica-International Journal of Drug Formulation and Biopharmaceutics. 28:1982;1.
5. Curtis, G. (2002). Patent challenge muddles Merck picture. Accessed from TheStreet.com on August 26, 2002.
6. Cyclosporin, Physicians Desk Reference (2001). Novartis Pharma AG, Basel, Switzerland.
7. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. Part 1. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. International Journal of Pharmaceutics. 125:1995;91.
8. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods. 44:2002;235.
9. Mendenhall, D. W. (2001). Trends in formulation science: building in developability. AAPS Newsmagazine, p. 13.
10. Peterson M.L., Morissette S.L., McNulty C., Goldsweig A., Shaw P., LeQuesne M., Monagle J., Encina N., Marchionna J., Johnson A., Gonzalez-Zagusti J., Lemmo A.V., Ellis S.J., Chima M.J., Almarsson O. Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. Journal of the American Chemical Society. 124:2002;10958.
11. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. International Journal of Pharmaceutics. 235:2002;179.